Pfizer Inc. (PFE) — closed signal from September 1, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on November 30, 2025.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published September 1, 2025
Pfizer looks cheap and pays solid income. On Aug 27, the FDA approved its updated COVID-19 vaccine for older and high-risk groups. A 7% dividend adds a cushion, and recent reviews say total cash returns to investors look supportive. Patent expirations are a real risk, but the fresh news and high income could help the stock recover over the next 3 months. Consider adding slowly within the stated price range.
Primary drivers
- FDA cleared Pfizer's updated COVID-19 shot for higher-risk adults
- Shares pay about a 7% yearly dividend, adding steady income for holders
- Overall cash returns to investors look supportive at current prices
- Price has fallen a lot lately, making the stock look beaten down
How it played out
PFE: target cleared during the window
Lyra published PFE on 2025-09-01 at 24.33 with a short-term thesis for 12% growth. The thesis pointed to FDA clearance for Pfizer's updated COVID-19 shot for higher-risk adults, about a 7% yearly dividend, supportive cash returns, and a beaten-down share price.
Inside the 2025-09-01 to 2025-11-30 window, PFE rose to 27.21 on 2025-10-03. That cleared the 26.78 target, while the listed peak gain was 11.8%. It ended at 25.74. The thesis mostly played out, though the final price gave back part of the move.
What happened during the window
On September 22, 2025, Pfizer announced an agreement to buy Metsera, a weight-loss drug developer. The deal was reported with an initial value of 4.9 billion dollars and potential consideration up to 7.3 billion dollars.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.